President Trump announced agreements with Novo Nordisk and Eli Lilly to expand access and lower prices for their obesity medicines; the administration said the deals will lower costs for some Medicare beneficiaries and offer starter oral doses at reduced prices if approved. The Oval Office event was interrupted when a pharmaceutical executive standing behind the president fainted and required assistance, briefly halting the announcement. The pricing accords are part of broader administration efforts to use negotiated or reference pricing to lower U.S. drug costs; industry and clinical groups have offered mixed reactions on implementation and clinical guidance. Clarification: the announced arrangements include government channels to sell drugs directly and price concessions tied to program participation.